erlotinib hydrochloride has been researched along with 3-hydroxyflavone in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (3-hydroxyflavone) | Trials (3-hydroxyflavone) | Recent Studies (post-2010) (3-hydroxyflavone) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,657 | 84 | 2,242 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | 3-hydroxyflavone (IC50) |
|---|---|---|---|
| Pyruvate kinase PKM | Homo sapiens (human) | 1.75 | |
| Cytochrome P450 1B1 | Homo sapiens (human) | 0.09 | |
| Aurora kinase B | Homo sapiens (human) | 4.29 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, RP; Tabasum, S | 1 |
1 other study(ies) available for erlotinib hydrochloride and 3-hydroxyflavone
| Article | Year |
|---|---|
Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition.
Topics: AC133 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Flavonoids; Flavonols; Humans; Hyaluronan Receptors; Lung Neoplasms; Neoplasm Invasiveness; Phenotype; Stem Cells | 2019 |